Contents

Search

plasma soluble urokinase plasminogen activator receptor

Indications: - elevated plasma soluble urokinase plasminogen activator receptor may be used to assess indication for anakinra in treatment of Covid-19 pneumonia

Related

urokinase plasminogen activator surface receptor; uPAR; U-PAR; monocyte activation antigen Mo3; CD87 (PLAUR, MO3, UPAR)

General

special chemistry test

References

  1. Bassett M FDA Authorizes IL-1 Drug for Hospitalized COVID Patients. Anakinra indicated for patients with pneumonia who are at risk of severe respiratory failure. MedPage Today November 9, 2022 https://www.medpagetoday.com/infectiousdisease/covid19/101662